CD8A and carcinoma: In pre-clinical murine models of MC38 colon carcinoma and TC-1 epithelial carcinoma, hetIL-15 treatment resulted in delayed primary tumor growth, expansion of NK and CD8+ T cell tumoral infiltration, and an increased CD8+/Treg ratio.